Sarepta Therapeutics (SRPT) Short term Debt (2016 - 2025)
Historic Short term Debt for Sarepta Therapeutics (SRPT) over the last 11 years, with Q3 2025 value amounting to $36.0 million.
- Sarepta Therapeutics' Short term Debt fell 6069.65% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.0 million, marking a year-over-year decrease of 6069.65%. This contributed to the annual value of $105.5 million for FY2023, which is N/A changed from last year.
- As of Q3 2025, Sarepta Therapeutics' Short term Debt stood at $36.0 million, which was down 6069.65% from $91.6 million recorded in Q3 2024.
- In the past 5 years, Sarepta Therapeutics' Short term Debt ranged from a high of $105.6 million in Q1 2024 and a low of $36.0 million during Q3 2025
- Over the past 3 years, Sarepta Therapeutics' median Short term Debt value was $91.6 million (recorded in 2024), while the average stood at $86.0 million.
- Over the last 5 years, Sarepta Therapeutics' Short term Debt had its largest YoY gain of 6069.65% in 2025, and its largest YoY loss of 6069.65% in 2025.
- Sarepta Therapeutics' Short term Debt (Quarter) stood at $105.5 million in 2023, then decreased by 13.17% to $91.6 million in 2024, then plummeted by 60.7% to $36.0 million in 2025.
- Its Short term Debt stands at $36.0 million for Q3 2025, versus $91.6 million for Q3 2024 and $91.5 million for Q2 2024.